Amnylin Surges 54% as Traders Bet on More Bids

Amnylin Surges 54% as Traders Bet on More Bids Play

March 29 (Bloomberg) -- Bloomberg's Julie Hyman reports that options traders are betting potential acquirers from AstraZeneca Plc to Bristol-Myers Squibb Co. will have to spend 26 percent more than its current price to buy Amylin Pharmaceuticals Inc. She speaks on Bloomberg Television's "InBusiness With Margaret Brennan."

  • On Air Now

    Bloomberg Surveillance Watch Now

  • Next

    In The Loop with Betty Liu

blog comments powered by Disqus